Warshaw Meredith G, Carey Vincent J, McFarland Elizabeth J, Dawson Liza, Abrams Elaine, Melvin Ann, Fairlie Lee, Spiegel Hans, Jay Jonathan, Agwu Allison L
1 Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
2 Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Clin Trials. 2017 Jun;14(3):314-318. doi: 10.1177/1740774517690734. Epub 2017 Jan 31.
Equipoise is usually discussed as an ethical issue in clinical trials. However, it also has practical implications.
Clinical equipoise is usually construed to mean uncertainty or disagreement among the expert clinician community. However, an individual physician's sense of equipoise may vary by location, based on the local standard of care or availability of specific treatment options, and these differences can affect providers' willingness to enroll participants into clinical trials. There are also logistical barriers to enrollment in international trials due to prolonged timelines for approvals by government agencies and ethical review boards.
A multinational clinical trial of bridging strategies for treatment of non-adherent HIV-infected youth, experienced differing perceptions of equipoise due to disparities in availability of treatment options by country. Unfortunately, the countries with most demand for the trial were those where the approval process was most delayed, and the study was closed early due to slow accrual.
When planning multicenter clinical trials, it is important to take into account heterogeneity among research sites and try to anticipate differences in equipoise and logistical factors between sites, in order to plan to address these issues at the design stage.
在临床试验中, equipoise通常作为一个伦理问题进行讨论。然而,它也具有实际意义。
临床 equipoise通常被理解为专家临床医生群体之间的不确定性或分歧。然而,个体医生的equipoise感可能因地点而异,这取决于当地的护理标准或特定治疗方案的可用性,而这些差异会影响提供者将参与者纳入临床试验的意愿。由于政府机构和伦理审查委员会的审批时间延长,国际试验的入组也存在后勤障碍。
一项针对未坚持治疗的HIV感染青年的治疗桥接策略的多国临床试验,由于不同国家治疗方案的可用性存在差异,对equipoise有不同的看法。不幸的是,对该试验需求最大的国家正是审批过程最延迟的国家,并且由于入组缓慢,该研究提前结束。
在规划多中心临床试验时,重要的是要考虑研究地点之间的异质性,并尝试预测不同地点在equipoise和后勤因素方面的差异,以便在设计阶段计划解决这些问题。